Articles

Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients

Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain; Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain
Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain; Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain
Hematopathology Unit, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona, Spain
Oncogenomic Laboratory, Hematology Service, Lausanne University Hospital, Lausanne, Switzerland
Cytogenetics and Hematological Genetics Services, Department of Genetics, University of Navarra, Pamplona, Spain
Hematopathology Unit, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona, Spain
Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
Hematology Section, St. Anna University Hospital, Ferrara, Italy
Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Department of Hematology, Consorcio Hospital General Universitario, Valencia, Spain
Cytogenetics Laboratory, Hematology Department, Fundación Jiménez Díaz, Madrid, Spain
Hematopathology Unit, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona, Spain
Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain; Applied Clinical Research in Hematological Malignances, Cancer Research Program, IMIMHospital del Mar, Barcelona, Spain
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain
Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain; Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain
Cytogenetics and Hematological Genetics Services, Department of Genetics, University of Navarra, Pamplona, Spain
Hematology Section, St. Anna University Hospital, Ferrara, Italy
Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
Hematology Department and Sorbonne Université, Hopital Pitie-Salpetriere, APHP, INSERM U1138, Paris, France
Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK
MLL Munich Leukemia Laboratory, Munich, Germany
Oncogenomic Laboratory, Hematology Service, Lausanne University Hospital, Lausanne, Switzerland
Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain; Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain
Haematologica Early view Mar 11, 2021 https://doi.org/10.3324/haematol.2020.274456